The Fibrin Pad CV Phase III Study

PHASE3CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

July 1, 2015

Study Completion Date

September 1, 2015

Conditions
Cardiovascular Disease
Interventions
BIOLOGICAL

EVARREST™ Fibrin Sealant Patch

BIOLOGICAL

Topical hemostat

Trial Locations (24)

2010

Clinical Investigation Site #73, Sydney

2050

Clinical Investigation Site #72, Camperdown

3050

Clinical Investigation Site #70, Melbourne

4000

Clinical Investigation Site #71, Brisbane

5042

Clinical Investigation Site #74, Bedford Park

9000

Clinical Investigation Site #40, Ghent

10016

Clinical Investigation Site #12, New York

19102

Clinical Investigation Site #20, Philadelphia

20814

Clinical Investigation Site #21, Bethesda

21201

Clinical Investigation Site #16, Baltimore

30342

Clinical Investigation Site #15, Atlanta

46290

Clinical Investigation Site #14, Indianapolis

63110

Clinical Investigation Site #17, St Louis

77030

Clinical Investigation Site #18, Houston

07503

Clinical Investigation Site #10, Paterson

Unknown

Clinical Investigation Site #82, Kanagawa

Clinical Investigation Site #81, Saitama

Clinical Investigation Site #80, Osaka

BS2 8HW

Clinical Investigation Site #33, Bristol

HU16 5JQ

Clinical Investigation Site #35, Cottingham

M13 9WL

Clinical Investigation Site #34, Manchester

AB25 2ZN

Clinical Investigation Site #32, Aberdeen

G81 4DY

Clinical Investigation Site #31, Clydebank

EH16 4SA

Clinical Investigation Site #30, Edinburgh

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT02040428 - The Fibrin Pad CV Phase III Study | Biotech Hunter | Biotech Hunter